COSELA™ (trilaciclib) Kickoff Analyst and Investor Summit hosted by G1 Therapeutics
Date and Time
Friday Apr 9, 2021
9:00 AM - 11:00 AM EDT
April 9
9 - 11 a.m.
Location
Virtual
Fees/Admission
A webcast of the event can be accessed on the Events & Presentations page of www.g1therapeutics.com. The webcast will be archived on the same page for 90 days following the event.
Website
Description
G1 Therapeutics will review its U.S. launch strategy for the first-in-class myeloprotection therapy, COSELA, in extensive-stage small cell lung cancer. COSELA is the only FDA-approved therapy that helps proactively deliver multilineage myeloprotection benefit to patients with extensive-stage small cell lung cancer being treated with chemotherapy. The program will also feature insights about the urgent need to proactively treat patients for myelosuppression from the following leading clinicians:
- Jared Weiss, M.D., Thoracic and Head/Neck Oncologist & Associate Professor, Division of Oncology, University of North Carolina at Chapel Hill
- Tajuana Bradley, MS, FNP-BC, Nurse Practitioner, Georgia Cancer Specialists
